Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591331 · ClinicalTrials.gov registry record · Phase 1
Phototoxicity Potential of NatrOVA Creme Rinse - 1%
A Phase 1 study, sponsored by ParaPRO.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00591331 is a Phase 1 study that has completed, run by ParaPRO. The registered enrollment target is 37 participants.
The verdict
NCT00591331, a Phase 1 study, has completed, sponsored by ParaPRO.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study will evaluate the primary irritation potential of NatrOVA Creme Rinse - 1% in humans, after exposure to UV radiation.
Interventions
- DRUG placebo
- DRUG Spinosad (the active ingredient in NatrOVA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-12 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591331
The ClinicalTrials.gov registry entry for NCT00591331 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ParaPRO, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00591331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00591331 about?
NCT00591331 is a clinical study titled "Phototoxicity Potential of NatrOVA Creme Rinse - 1%". This study will evaluate the primary irritation potential of NatrOVA Creme Rinse - 1% in humans, after exposure to UV radiation.
What is the current status of trial NCT00591331?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2007-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00591331?
The interventions under investigation include: placebo (DRUG), Spinosad (the active ingredient in NatrOVA) (DRUG).
Who is sponsoring clinical trial NCT00591331?
This trial is sponsored by ParaPRO, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.